O&G SAQs · Antenatal care — fetal medicine and immunohaematology
Rh(D) alloimmunisation and anti-D prophylaxis — structured SAQ (15 marks)
FRANZCOG-format structured SAQ on Rh(D) alloimmunisation and anti-D prophylaxis: routine antenatal dosing (NBA/RANZCOG 2024), sensitising-event and postpartum management with fetomaternal haemorrhage quantification, and surveillance of the previously-affected alloimmunised pregnancy with serial MCA-PSV. Per-sub-part marking rubric included.
On this page
Study tools
Target exams
How this SAQ is marked
Twelve SAQs, 180 marks, two 2-hour papers — roughly 15 marks and 20 minutes each. Marks come from specifics: the dose, the route, the timing, the threshold, the window. Write in short labelled points, not prose. [4]
Reveal model answer and mark schemeShowHide
(a) Routine antenatal anti-D prophylaxis (3 marks)
One mark per element; full marks need drug, dose, route and timing. [4]
- Drug and product: Rh(D) immunoglobulin (anti-D), intramuscular.[4]
- Dose and timing: two doses of 625 IU, one at 28 weeks and one at 34 weeks, to the RhD-negative woman without preformed anti-D.[4]
- Confirm negative antibody screen before the first dose (a positive screen means sensitisation has already occurred and prophylactic anti-D is pointless).[2]
(b) Antepartum haemorrhage at 26 weeks — sensitising-event management (3 marks)
One mark per point. [4]
- Give anti-D for the event: because the bleed is over 12 weeks, the dose is 625 IU IM, given as soon as possible (within 72 hours).[4]
- Quantify the fetomaternal haemorrhage with a Kleihauer-Betke test (or flow cytometry); the standard 625 IU covers up to 6 mL of fetal red cells.[4]
- Top up for the excess: the Kleihauer estimates 8 mL, so 2 mL exceeds the 6 mL cover — give additional anti-D at 100 IU per 1 mL of fetal red cells over 6 mL, so 200 IU additional. Do not delay the initial 625 IU while awaiting the result.[4]
(c) Postpartum management (3 marks)
One mark per point. [4]
- Confirm the infant is RhD-positive on cord blood (blood group and direct antiglobulin test) before giving postpartum anti-D.[4]
- Give 625 IU IM within 72 hours, without waiting for the Kleihauer result.[4]
- Quantify the fetomaternal haemorrhage (Kleihauer or flow cytometry); give additional anti-D at 100 IU per mL of fetal red cells over 6 mL if the bleed is larger than the standard cover.[4]
(d) Previously-affected alloimmunised pregnancy (6 marks)
The high-value part. Marks for the surveillance pathway, the key thresholds, and the management triggers. [2][3]
- Anti-D is now useless — she is already sensitised; do not give prophylactic anti-D.[2]
- Titres are non-predictive in a previously affected pregnancy. Do NOT monitor with serial titres; go straight to serial middle cerebral artery peak systolic velocity (MCA-PSV) Doppler from 16 to 18 weeks.[2]
- The action threshold: when MCA-PSV rises above 1.5 multiples of the median for gestation, perform fetal blood sampling with an intrauterine transfusion (IUT) ready, unless gestation makes delivery safer.[3]
- Refer to a fetal medicine centre with intrauterine transfusion capability.[3]
- IUT technique (one mark): intravascular via cordocentesis into the umbilical vein at the placental insertion; O-negative, CMV-negative, irradiated, crossmatch-compatible packed cells; repeat guided by predicted haemoglobin decline (about 1 g/dL per week) and serial MCA-PSV.[2]
- Outcome and neonatal plan (one mark): perinatal survival after IUT exceeds 90 percent; plan neonatal cord blood group, direct antiglobulin test, bilirubin and haemoglobin, with phototherapy and top-up readiness; counsel on recurrence and escalation next time.[2]
References4ShowHide
- [1]Mari G, Deter RL, Carpenter RL, et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses N Engl J Med, 2000.PMID 10620643
- [2]Moise KJ Jr Management of rhesus alloimmunization in pregnancy Obstet Gynecol, 2008.PMID 18591322
- [3]Mari G, Norton ME, Stone J, et al. Society for Maternal-Fetal Medicine (SMFM) Clinical Guideline #8: the fetus at risk for anemia—diagnosis and management Am J Obstet Gynecol, 2015.PMID 25824811
- [4]Glazebrook B, Akers C, Bielby L, Bastin K, Von Wielligh K, Daly J Quality audit of the guidelines for the use of RhD immunoglobulin in obstetrics: Are we getting it right? Aust N Z J Obstet Gynaecol, 2020.PMID 32424867